Reaction

Nasal Disorder reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,632 reports · 62 co-occurring drugs

As of the last recalculation, Nasal Disorder appears in 2,632 FAERS reports alongside 62 co-occurring drug terms. The strongest observed disproportionality signal is VALPROATE SODIUM (PRR 24.3).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Valproate Sodium	62	24.3	24.3
Ciclesonide	37	21.8	21.8
Anastrozole Tablets	52	19.5	19.6
Rabeprazole	45	16.3	16.4
Mepolizumab	94	15.5	15.5
Fluticasone Furoate	22	14.5	14.5
Mometasone Furoate	73	14.2	14.2
Anastrozole	54	11.9	11.9
Cetirizine Hcl	13	11.3	11.3
Acetaminophen, Chlorpheniramine Maleate, Phenylephrine Hcl	66	10.7	10.7
Fluticasone Propionate And Salmeterol Xinafoate	72	9.7	9.7
Pertuzumab	33	9.7	9.7
Ketoprofen	16	9.7	9.7
Felodipine Extended-Release Tablets	13	9.1	9.1
Felodipine	13	9.1	9.1
Zoledronic Acid	45	9.0	9.0
Fluticasone Propionate	140	9.0	9.0
Filgrastim	39	8.3	8.3
Fluticasone Furoate And Vilanterol Trifenatate	37	8.2	8.2
Omalizumab	85	8.1	8.1
Psyllium Husk	10	8.0	8.0
Dutasteride	8	7.8	7.8
Fluticasone Propionate Nasal	29	7.6	7.6
Budesonide And Formoterol Fumarate Dihydrate	86	7.2	7.2
Montelukast Sodium	103	6.9	6.9
Mometasone	15	6.5	6.5
Loratadine And Pseudoephedrine Sulfate	6	6.0	6.0
Metolazone	8	5.6	5.6
Benralizumab	14	5.6	5.6
Sunitinib Malate	27	5.5	5.5
Naproxen Sodium Tablet, Coated	9	5.3	5.3
Naproxen Sodium, Coated Tablets	9	5.3	5.3
Naproxen Sodium 220Mg	9	5.3	5.3
Tiotropium Bromide	86	5.1	5.1
Alirocumab	16	5.1	5.1
Montelukast	52	5.0	5.0
Dofetilide	6	4.5	4.5
Nevirapine	5	4.4	4.4
Docetaxel Anhydrous	36	4.3	4.3
Docetaxel	36	4.3	4.3
Palbociclib	50	4.2	4.2
Loratadine Tablet	28	4.2	4.2
Trastuzumab	33	3.8	3.8
Umeclidinium Bromide And Vilanterol Trifenatate	8	3.8	3.8
Calcium, Magnesium, Potassium, And Sodium Oxybates	4	3.7	3.7
Fexofenadine Hydrochloride	10	3.6	3.6
Alpelisib	4	3.6	3.6
Vismodegib	4	3.6	3.6
Eptinezumab-Jjmr	4	3.5	3.5
Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide	4	3.1	3.1
Paclitaxel (Aibumin-Bound)	32	3.1	3.1
Diclofenac Potassium, Film Coated	3	2.8	2.8
Diclofenac Potassium Tablets	3	2.8	2.8
Pirfenidone	13	2.5	2.5
Esketamine Hydrochloride	5	2.2	2.2
Nirmatrelvir And Ritonavir	15	2.2	2.2
Ranibizumab	7	2.1	2.1
Palivizumab	4	2.1	2.1
Apalutamide	3	2.0	2.0
Sarilumab	6	1.8	1.8
Evolocumab	34	1.7	1.7
Dupilumab	80	1.3	1.3

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.